Agios Pharmaceuticals, Inc. (AGIO)

Agios Pharmaceuticals Balance Sheet

Financials in millions USD. Fiscal year is January - December.

Fiscal Year	TTM	FY 2024	FY 2023	FY 2022	FY 2021	FY 2020
Period Ending	Jun 30, 2025	Dec 31, 2024	Dec 31, 2023	Dec 31, 2022	Dec 31, 2021	Dec 31, 2020
Cash & Equivalents	80.87	76.25	88.21	139.26	203.13	127.44
Short-Term Investments	858.07	817.46	688.72	643.86	816.89	445.49
Cash & Short-Term Investments	938.94	893.71	776.93	783.12	1,020	572.93
Cash Growth	64.76%	15.03%	-0.79%	-23.23%	78.04%	1.43%
Accounts Receivable	4.99	4.11	2.81	2.21	-	-
Other Receivables	-	-	1.1	0.3	7.28	-
Receivables	4.99	4.11	3.91	2.51	7.28	-
Inventory	30.85	27.62	19.08	8.49	-	-
Prepaid Expenses	44.69	40.17	33.92	38.66	36.94	15.89
Other Current Assets	-	-	-	-	-	47.86
Total Current Assets	1,019	965.6	833.84	832.77	1,064	636.68
Property, Plant & Equipment	47.36	54.55	69.79	88.12	104.23	116.07
Long-Term Investments	400.47	638.32	29.44	313.87	266.38	97.61
Other Long-Term Assets	3.94	4.72	4.06	3.96	2.9	2.6
Total Assets	1,471	1,663	937.12	1,239	1,438	852.95
Accounts Payable	17.53	16.64	9.78	18.62	16.7	17.72
Accrued Expenses	35.29	46.86	43.17	30.35	31.97	30.8
Current Portion of Leases	17.59	16.78	15.01	13.66	11.16	7.41
Current Income Taxes Payable	-	0.87	-	-	-	-
Other Current Liabilities	-	-	-	-	-	38.46
Total Current Liabilities	70.41	81.16	67.96	62.63	59.83	94.39
Long-Term Leases	31.17	40.21	56.99	72	85.94	97.79
Other Long-Term Liabilities	0.1	0.88	1.16	3.28	-	261.27
Total Liabilities	101.68	122.24	126.1	137.9	145.76	453.45
Common Stock	0.07	0.07	0.07	0.07	0.07	0.07
Additional Paid-In Capital	2,522	2,494	2,437	2,386	2,334	2,243
Retained Earnings	-350.23	-148.92	-822.65	-470.56	-238.76	-1,843
Treasury Stock	-802.49	-802.49	-802.49	-802.49	-802.49	-
Comprehensive Income & Other	0.66	-1.52	-0.44	-12.54	-1.2	0.11
Shareholders' Equity	1,370	1,541	811.02	1,101	1,292	399.5
Total Liabilities & Equity	1,471	1,663	937.12	1,239	1,438	852.95
Total Debt	48.76	56.99	72	85.66	97.09	105.2
Net Cash (Debt)	1,291	1,475	734.37	1,011	1,189	565.34
Net Cash Growth	122.27%	100.86%	-27.39%	-14.96%	110.37%	-6.42%
Net Cash Per Share	22.08	25.48	13.20	18.46	19.67	8.19
Filing Date Shares Outstanding	58.1	57.3	56.19	55.29	54.64	69.6
Total Common Shares Outstanding	58.04	57.16	55.95	55.04	54.33	69.29
Working Capital	949.05	884.44	765.88	770.14	1,004	542.28
Book Value Per Share	23.60	26.96	14.50	20.00	23.78	5.77
Tangible Book Value	1,370	1,541	811.02	1,101	1,292	399.5
Tangible Book Value Per Share	23.60	26.96	14.50	20.00	23.78	5.77
Machinery	-	29.76	29.73	35.12	33.8	35.49
Construction In Progress	-	0.9	0.61	0.66	7.37	4.11
Leasehold Improvements	-	37.52	37.28	37.28	32.73	32.57

Updated Jul 31, 2025. Source: S&P Global Market Intelligence. Standard template. Financial Sources.

SEC Filings: 10-K · 10-Q